Ask Aeroz

Type the question you actually came here with.

Resources · Product safety

A Texas Med Spa Injected More Botox Than It Bought From AbbVie

FDA got the purchase records from the manufacturer. The first DSCSA warning letter ever sent to a dispenser. On 1 April the FDA told a Texas medical spa…

By Aeroz · 8 min read · Last updated: November 20, 2026

Originally published on Medium.

FDA got the purchase records from the manufacturer. The first DSCSA warning letter ever sent to a dispenser.

On 1 April the FDA told a Texas medical spa it had injected more Botox into patients than it ever bought from AbbVie.

Sit with what that means before the regulatory detail. Every unit above what the authorised distributor sold them came from somewhere else. Nobody can say what was in those units: not the clinic, not AbbVie, not the FDA. They went into people’s faces anyway.

That is the problem in this piece, and it appears twice in two different states, which is the second half of the article. The first half is how the agency found it, because it did not test a single vial.

What the arithmetic found

The letter went to Pure Indulgence Aesthetics in Southlake, Texas, and it is dated 1 April 2026. FDA had inspected over three days the previous December.

The agency obtained AbbVie’s purchase records for the facility, covering vials received between 18 December 2024 and 1 December 2025. The quantities are redacted in the published letter. It set those against the practice’s own patient treatment records and found, in the letter’s words as reported by RAPS, that the facility had dispensed “significantly more” units than it had purchased.

The practice offered no explanation during the inspection. Sidley Austin, reviewing the letter, notes a detail that is hard to read charitably: the only larger-than-usual order on the record was dated after the inspectors arrived.

There is no laboratory finding in that part of the case. No seizure, no informant, no counterfeit identified. Two columns of numbers that did not reconcile, one of which came from the manufacturer.

The vial in the bin

The second count is more conventional and it is the one people will remember.

Inspectors recovered an unlabelled clear vial with a ring of white powder in it from the facility’s waste. Laboratory analysis confirmed botulinum neurotoxin type A. FDA said it was “not an authentic AbbVie Botox vial,” the vial’s shape being inconsistent with authentic packaging, and it carried no product identifier. The manager denied knowledge of it.

FDA cited that under section 582(d)(2) of the Federal Food, Drug, and Cosmetic Act, engaging in transactions involving product without a required product identifier. The purchase discrepancy was cited under section 582(d)(3), conducting transactions with unauthorized trading partners, with AbbVie identified as the authorized trading partner under section 581(2)(A).

Two other findings in the response are worth any practice manager’s attention. The facility said a retrospective review had found no adverse events; FDA said it could not verify that and raised concerns about tracing product in a recall. The facility said it had appointed a designated drug custodian and then provided no documentation identifying who that was.

The practice was given fifteen working days to respond.

You are a dispenser

Here is the part most aesthetic practices do not know, and it is the reason this letter matters beyond one business in Southlake.

Section 581(3) of the Act defines a dispenser as any person authorized to dispense or administer prescription drugs. Administer. A medical spa injecting a prescription product is a dispenser under the Drug Supply Chain Security Act, with the obligations that attach to one, whether or not anybody in the building has ever heard of the statute.

Sidley describes the letter as “what appears to be the first-ever warning letter” to a dispenser under the DSCSA. The firm’s headline drops the hedge and the body keeps it, and we have kept it too, because nobody has published a survey proving no earlier letter exists.

What Sidley says next is the part to plan around. FDA can act here without proving that anything was adulterated or misbranded, which it calls “potentially lowering the evidentiary threshold.” The firm expects the action is “unlikely to be isolated” and says it “establishes a template,” and it names the exposed categories: medical spas, individual practitioners, and any entity that administers prescription drugs under physician supervision. Entities, in its words, that “may have never considered themselves DSCSA-regulated.”

And providers should assume, Sidley writes, that FDA can and will go to manufacturers and other supply chain partners for records.

Colorado, and what it looks like when the product is wrong

The Texas case is a records case. Nobody was reported hurt. For the other half of the picture, the CDC published an investigation on 8 October.

Three women developed neurological symptoms within a day of being injected at a Colorado medical spa, and it is worth reading the list in plain words rather than clinical ones.

Patient A had 24 units in the upper brow and forehead. Within the day she had numbness and tingling in her arms and legs, a stiff neck, trouble speaking, a headache and blurred vision. Patient B had 3 units and had trouble speaking, a headache and blurred vision. Patient C had 10 units and had trouble breathing, a headache and weakness in her arms and legs.

None of them needed hospital treatment and all three recovered. CDC calls the symptoms transient and we are not going to inflate them. But trouble speaking and trouble breathing after a cosmetic injection is the thing the rest of this article is about, and it reads differently from “dysphonia” and “dyspnea.”

The product was a botulinum toxin approved in other countries and not approved for use in the United States. The provider said it had been bought through an online supplier. The provider was a licensed medical practitioner, and both approved and unapproved products were on the premises.

The investigation did not start with a complaint about the spa. Rocky Mountain Poison and Drug Safety flagged patient A to public health authorities in January, and the Colorado Department of Public Health and Environment went looking. It surveyed 52 patients injected at the facility between December 2025 and January 2026, got 27 responses, and found patients B and C that way.

And here is where Colorado turns into the same problem as Texas. The lot actually administered was not available for testing. CDC tested a different lot obtained from the spa and found active toxin with no elevated levels and no contaminants, which tells you about that lot and nothing about the one that was injected.

So the investigation could not establish what caused the symptoms. Three women were injected with something, something went wrong within the day, and there is no way back to what it was, because the vials were gone.

That is the Texas finding wearing different clothes. In Southlake nobody could say where the surplus units came from. In Colorado nobody could say what was in the ones that caused symptoms. Neither is a detection failure. Both are the same inability to say what went into a particular patient.

The inspection also found a preservative-containing diluent used inappropriately, single-dose vials used across multiple patients, inadequate temperature monitoring, and reconstituted unlabelled product used past its beyond-use date. The provider was ordered to stop using the unapproved products, and a complaint was filed against the licence with the Colorado Department of Regulatory Agencies.

CDC put the national context at roughly 9.8 million cosmetic botulinum toxin injections in the United States in 2024. Its own recommendation is that people should “seek treatment only from licensed providers administering FDA-approved BoNT products,” which is a harder test than it sounds, because the Colorado provider was licensed.

CDC also notes in the same report that medical spas may be regulated as dispensers under the DSCSA, and cites the Texas warning letter. The two threads are not ours to join. The agency joined them.

What would have had to be provable, at item level

Run the two cases next to each other and the same gap sits in both.

In Texas the finding was a difference between units bought and units administered. In Colorado the finding could not be completed, because the lot that was injected could not be produced. Neither is a detection problem. Both are a record problem, and specifically a per-unit record problem: how many of this product came into this building, which patient received each one, and which ones are left.

The reconciliation FDA performed is one any practice can run on itself, monthly, and the only thing it requires is that every vial received is recorded against the treatment it was used for. A practice that does that finds its own discrepancy in a spreadsheet. A practice that does not finds out when an inspector arrives holding records from its supplier.

The more interesting side of this is upstream. FDA had to go to AbbVie after the fact and ask for purchase records, then do the comparison by hand for one facility over about twelve months. A manufacturer whose product carries a unit-level identity that resolves on use is running that comparison continuously, across every account, without a subpoena and without an inspection. The discrepancy that took a three-day inspection and a document request in Southlake is a query.

Aeroz tracks counterfeit enforcement, recalls and supply chain failures in regulated industries, three times a week. Follow for the next one. aeroz.io · [email protected]

Read the original on Medium →

Next step. If a regulation with a date applies to your product, start with the compliance guides or a fixed-fee audit.
Free 20-minute call

Talk it through — in 20 minutes.

Tell us what you make, where it ships and what you have to prove. We show you how Aeroz would tag and trace it, which rules apply to you and when, and what it would take to go live.

Length
20 minutes
Cost
Free
With
Our team
Commitment
None
Free 20 minutes No commitment

What we cover

  • Which rules apply to your products, and by when.
  • How the tags go on, with the labelers you already run.
  • What one unit's record looks like, from line to customer.
  • Cost and time to go live for your volumes.